WO2011161646A3 - Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof - Google Patents

Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof Download PDF

Info

Publication number
WO2011161646A3
WO2011161646A3 PCT/IB2011/052764 IB2011052764W WO2011161646A3 WO 2011161646 A3 WO2011161646 A3 WO 2011161646A3 IB 2011052764 W IB2011052764 W IB 2011052764W WO 2011161646 A3 WO2011161646 A3 WO 2011161646A3
Authority
WO
WIPO (PCT)
Prior art keywords
alvimopan
solvate
preparation
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/IB2011/052764
Other languages
French (fr)
Other versions
WO2011161646A2 (en
Inventor
Anand Prakash Tiwari
Shyam Sunder Verma
Shravan Kumar Singh
Kaptan Singh
Mohan Prasad
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2011161646A2 publication Critical patent/WO2011161646A2/en
Publication of WO2011161646A3 publication Critical patent/WO2011161646A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/72—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/73—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to novel intermediates, ethyl N-[(2S)-2 -benzyl-3- hydroxypropanoyl]glycinate and ethyl N-[(2S)-2-benzyl-3-{[(4-bromophenyl)sulfonyl] oxy}propanoyl]glycinate, and processes for their preparation. The present invention also relates to a process for producing alvimopan or its pharmaceutically acceptable salt or solvate thereof using these novel intermediates.(A).
PCT/IB2011/052764 2010-06-25 2011-06-23 Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof WO2011161646A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1495/DEL/2010 2010-06-25
IN1495DE2010 2010-06-25

Publications (2)

Publication Number Publication Date
WO2011161646A2 WO2011161646A2 (en) 2011-12-29
WO2011161646A3 true WO2011161646A3 (en) 2012-03-15

Family

ID=44583623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/052764 WO2011161646A2 (en) 2010-06-25 2011-06-23 Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof

Country Status (1)

Country Link
WO (1) WO2011161646A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013080221A2 (en) * 2011-12-01 2013-06-06 Hetero Research Foundation Process for alvimopan
US10093625B2 (en) 2014-09-09 2018-10-09 Msn Laboratories Private Limited Process for the preparation of [[2(S)-[[4(R)-(3-hydroxyphenyl)-3(R),4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]amino]acetic acid dihydrate
CN105037248B (en) * 2015-08-10 2017-10-03 山东罗欣药业集团股份有限公司 A kind of synthetic method of Aiweimopan

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
EP0657428A1 (en) * 1993-12-08 1995-06-14 Eli Lilly And Company Preparation of 3,4,4-trisubstitutedpiperidinyl-n-alkylcarboxylates and intermediates, useful as opioid antagonists
EP0937710A1 (en) * 1998-02-16 1999-08-25 Ajinomoto Co., Inc. Method for producing an optically active phenylpropionic acid derivative
CN100383121C (en) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 Substituted benzyl ester and its preparation process and novel process for preparing substituted mopipe therefrom
CN101967118A (en) * 2010-10-14 2011-02-09 成都名阳药业有限公司 Preparation method of alvimopan
CN102127005A (en) * 2011-01-05 2011-07-20 博瑞生物医药技术(苏州)有限公司 Intermediate of alvimopan and synthesis method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794510B2 (en) 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US6992090B2 (en) 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists
EP0657428A1 (en) * 1993-12-08 1995-06-14 Eli Lilly And Company Preparation of 3,4,4-trisubstitutedpiperidinyl-n-alkylcarboxylates and intermediates, useful as opioid antagonists
EP0937710A1 (en) * 1998-02-16 1999-08-25 Ajinomoto Co., Inc. Method for producing an optically active phenylpropionic acid derivative
CN100383121C (en) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 Substituted benzyl ester and its preparation process and novel process for preparing substituted mopipe therefrom
CN101967118A (en) * 2010-10-14 2011-02-09 成都名阳药业有限公司 Preparation method of alvimopan
CN102127005A (en) * 2011-01-05 2011-07-20 博瑞生物医药技术(苏州)有限公司 Intermediate of alvimopan and synthesis method thereof

Also Published As

Publication number Publication date
WO2011161646A2 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
WO2013179300A3 (en) A process for the preparation of vildagliptin and its intermediate thereof
EP3715345A3 (en) Preparation of lfa-1 inhibitor and polymorph thereof
WO2015100213A3 (en) Process-scale synthesis of urolithins
WO2010092090A3 (en) Novel salts of sitagliptin
MX342807B (en) Pharmaceutically acceptable cocrystals of n-[2-(7-methoxy-1-napht yl)ethyl]acetamide and methods of their preparation.
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
WO2012042534A3 (en) Preparation of r-sitagliptin and intermediates thereof
WO2011060213A3 (en) Preparation of sitagliptin and salts thereof
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
WO2012038975A3 (en) Processes for the preparation of asenapine and intermediates thereof
WO2012004396A3 (en) Process of preparing a thrombin specific inhibitor
WO2012070062A3 (en) Novel polymorph of nilotinib hydrochloride
EP2388261A3 (en) Improved process for the preparation of carbapenem using carbapenem intermediates and recovery of carbapenem
WO2010070449A3 (en) Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2010140765A2 (en) Novel method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
WO2010129918A8 (en) Triptolide prodrugs
WO2011025932A3 (en) Preparation of sitagliptin and salts thereof
WO2008117305A3 (en) A novel process for preparing pregabalin and its acid addition salts
WO2014036502A3 (en) Tetracycline compounds
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2013111158A3 (en) Process for the preparation of dpp-iv inhibitor
WO2011089126A3 (en) Novel retigabine composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11743629

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11743629

Country of ref document: EP

Kind code of ref document: A2